No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 11 of the 28 quarters in the window, leaving 17 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 7.9x · 10Y median 9.2x · 28th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 29
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-05-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-05-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-05-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-05-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-05-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:27:37.502Z. Latest historical point 2026-05-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Mirum Pharmaceuticals, Inc. (MIRM) stock was $79.64 as of Oct 6, 2026, 12:25 PM EDT, down 2.20% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +11.6% · 3-year avg +40.1%/yr · 5-year avg +37.2%/yr
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions.
Biotechnology · Foster City, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.53
Revenue Est.
$178.06M
Last Quarter Results
EPS
$-0.80
vs Estimate
$-0.75
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MIRM | $4.86B | $79.64 | -2.20% | +11.57% | +37.24% | N/A | N/A |
| 2ORKA | $4.84B | $80.31 | -4.82% | +323.68% | +32.76% | -13.93% | vs MIRM |
| 3DNTH | $4.82B | $86.18 | -2.11% | +150.87% | -5.50% | N/A | vs MIRM |
| 4DFTX | $4.70B | $35.37 | -2.37% | +187.00% | +1.43% | N/A | vs MIRM |
| 5LFST | $4.69B | $12.10 | -1.02% | +120.94% | -1.46% | N/A | vs MIRM |
| 6ERAS | $5.05B | $14.55 | -1.15% | +503.05% | -8.34% | N/A | vs MIRM |
forward FY estimate
N/A
$176.20M
vs Estimate
$166.33M
Consensus Rating
Based on 14 analysts
Average Price Target
$145.79
+83.1% upside
Low
$118.00
Current
$79.64
High
$195.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.81 | $-0.49 | $0.06 | 3 |
| Quarter ending Dec 2026 | $-1.20 | $-0.60 | $-0.11 | 4 |
| Quarter ending Mar 2027 | $-0.34 | $-0.33 | $-0.31 | 1 |
| Quarter ending Jun 2027 | $-0.27 | $-0.26 | $-0.25 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-15.48 | $-15.11 | $-14.20 | 7 |
| FY 2027 | $-4.84 | $-0.66 | $3.14 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $172.08M | $178.06M | $180.22M | 8 |
| Quarter ending Dec 2026 | $181.22M | $183.81M | $188.63M | 8 |
| Quarter ending Mar 2027 | $184.03M | $189.87M | $195.97M | 4 |
| Quarter ending Jun 2027 | $192.34M | $198.44M | $204.81M | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $689.39M | $697.92M | $704.91M | 10 |
| FY 2027 | $754.16M | $816.98M | $864.70M | 9 |
